vs
碧迪（BDX）与恩智浦（NXPI）财务数据对比。点击上方公司名可切换其他公司
碧迪的季度营收约是恩智浦的1.7倍（$5.3B vs $3.2B），恩智浦净利率更高（35.3% vs 7.3%，领先28.0%），碧迪同比增速更快（-0.4% vs -5.0%），恩智浦自由现金流更多（$714.0M vs $549.0M），过去两年碧迪的营收复合增速更高（2.0% vs 0.9%）
碧迪（Becton Dickinson）是美国跨国医疗科技企业，核心业务包括研发、生产及销售医用器械、仪器系统与试剂产品，同时在特定领域提供专业咨询及数据分析服务，业务覆盖全球多国，在全球医疗技术领域具备领先地位。
恩智浦是总部位于荷兰埃因霍温的半导体设计与制造企业，为2024年市值排名欧洲第三的半导体公司。目前集团在全球30多个国家拥有约3.4万名员工，2024年总营收达126.1亿美元。
BDX vs NXPI — 直观对比
营收规模更大
BDX
是对方的1.7倍
$3.2B
营收增速更快
BDX
高出4.6%
-5.0%
净利率更高
NXPI
高出28.0%
7.3%
自由现金流更多
NXPI
多$165.0M
$549.0M
两年增速更快
BDX
近两年复合增速
0.9%
损益表 — Q1 FY2026 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $5.3B | $3.2B |
| 净利润 | $382.0M | $1.1B |
| 毛利率 | 45.9% | 59.5% |
| 营业利润率 | 10.5% | — |
| 净利率 | 7.3% | 35.3% |
| 营收同比 | -0.4% | -5.0% |
| 净利润同比 | 24.0% | 147.0% |
| 每股收益（稀释后） | $1.34 | $4.43 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BDXNXPI
| Q1 26 | — | $3.2B | ||
| Q4 25 | $5.3B | $3.3B | ||
| Q3 25 | $5.9B | $3.2B | ||
| Q2 25 | $5.5B | $2.9B | ||
| Q1 25 | $5.3B | $2.8B | ||
| Q4 24 | $5.2B | $3.1B | ||
| Q3 24 | $5.4B | $3.3B | ||
| Q2 24 | $5.0B | $3.1B |
净利润BDXNXPI
| Q1 26 | — | $1.1B | ||
| Q4 25 | $382.0M | $455.0M | ||
| Q3 25 | $493.0M | $631.0M | ||
| Q2 25 | $574.0M | $445.0M | ||
| Q1 25 | $308.0M | $490.0M | ||
| Q4 24 | $303.0M | $495.0M | ||
| Q3 24 | $400.0M | $718.0M | ||
| Q2 24 | $487.0M | $658.0M |
毛利率BDXNXPI
| Q1 26 | — | 59.5% | ||
| Q4 25 | 45.9% | 54.2% | ||
| Q3 25 | 47.5% | 56.3% | ||
| Q2 25 | 47.8% | 53.4% | ||
| Q1 25 | 42.8% | 55.0% | ||
| Q4 24 | 43.2% | 53.9% | ||
| Q3 24 | 45.7% | 57.4% | ||
| Q2 24 | 46.2% | 57.3% |
营业利润率BDXNXPI
| Q1 26 | — | — | ||
| Q4 25 | 10.5% | 22.3% | ||
| Q3 25 | 11.8% | 28.1% | ||
| Q2 25 | 16.0% | 23.5% | ||
| Q1 25 | 10.4% | 25.5% | ||
| Q4 24 | 8.8% | 21.7% | ||
| Q3 24 | 11.4% | 30.5% | ||
| Q2 24 | 12.1% | 28.7% |
净利率BDXNXPI
| Q1 26 | — | 35.3% | ||
| Q4 25 | 7.3% | 13.6% | ||
| Q3 25 | 8.4% | 19.9% | ||
| Q2 25 | 10.4% | 15.2% | ||
| Q1 25 | 5.8% | 17.3% | ||
| Q4 24 | 5.9% | 15.9% | ||
| Q3 24 | 7.4% | 22.1% | ||
| Q2 24 | 9.8% | 21.0% |
每股收益（稀释后）BDXNXPI
| Q1 26 | — | $4.43 | ||
| Q4 25 | $1.34 | $1.80 | ||
| Q3 25 | $1.71 | $2.48 | ||
| Q2 25 | $2.00 | $1.75 | ||
| Q1 25 | $1.07 | $1.92 | ||
| Q4 24 | $1.04 | $1.93 | ||
| Q3 24 | $1.37 | $2.79 | ||
| Q2 24 | $1.68 | $2.54 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $740.0M | $3.7B |
| 总债务越低越好 | — | $11.7B |
| 股东权益账面价值 | $25.3B | $10.9B |
| 总资产 | $54.8B | $27.1B |
| 负债/权益比越低杠杆越低 | — | 1.07× |
8季度趋势，按日历期对齐
现金及短期投资BDXNXPI
| Q1 26 | — | $3.7B | ||
| Q4 25 | $740.0M | $3.3B | ||
| Q3 25 | $641.0M | $3.5B | ||
| Q2 25 | $735.0M | $3.2B | ||
| Q1 25 | $667.0M | $4.0B | ||
| Q4 24 | $711.0M | $3.3B | ||
| Q3 24 | $1.7B | $2.7B | ||
| Q2 24 | $4.5B | $2.9B |
总债务BDXNXPI
| Q1 26 | — | $11.7B | ||
| Q4 25 | — | $11.0B | ||
| Q3 25 | — | $11.0B | ||
| Q2 25 | — | $9.5B | ||
| Q1 25 | — | $10.2B | ||
| Q4 24 | — | $10.4B | ||
| Q3 24 | — | $9.7B | ||
| Q2 24 | — | $9.7B |
股东权益BDXNXPI
| Q1 26 | — | $10.9B | ||
| Q4 25 | $25.3B | $10.1B | ||
| Q3 25 | $25.4B | $10.0B | ||
| Q2 25 | $25.5B | $9.6B | ||
| Q1 25 | $25.2B | $9.3B | ||
| Q4 24 | $25.2B | $9.2B | ||
| Q3 24 | $25.9B | $9.4B | ||
| Q2 24 | $25.9B | $9.0B |
总资产BDXNXPI
| Q1 26 | — | $27.1B | ||
| Q4 25 | $54.8B | $26.6B | ||
| Q3 25 | $55.3B | $26.4B | ||
| Q2 25 | $54.9B | $25.3B | ||
| Q1 25 | $54.5B | $25.2B | ||
| Q4 24 | $54.7B | $24.4B | ||
| Q3 24 | $57.3B | $23.7B | ||
| Q2 24 | $55.6B | $23.2B |
负债/权益比BDXNXPI
| Q1 26 | — | 1.07× | ||
| Q4 25 | — | 1.09× | ||
| Q3 25 | — | 1.09× | ||
| Q2 25 | — | 0.99× | ||
| Q1 25 | — | 1.10× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $657.0M | — |
| 自由现金流经营现金流 - 资本支出 | $549.0M | $714.0M |
| 自由现金流率自由现金流/营收 | 10.5% | 22.4% |
| 资本支出强度资本支出/营收 | 2.1% | 2.5% |
| 现金转化率经营现金流/净利润 | 1.72× | — |
| 过去12个月自由现金流最近4个季度 | $2.6B | $2.7B |
8季度趋势，按日历期对齐
经营现金流BDXNXPI
| Q1 26 | — | — | ||
| Q4 25 | $657.0M | $891.0M | ||
| Q3 25 | $1.4B | $585.0M | ||
| Q2 25 | $1.2B | $779.0M | ||
| Q1 25 | $164.0M | $565.0M | ||
| Q4 24 | $693.0M | $391.0M | ||
| Q3 24 | $1.2B | $779.0M | ||
| Q2 24 | $1.3B | $761.0M |
自由现金流BDXNXPI
| Q1 26 | — | $714.0M | ||
| Q4 25 | $549.0M | $793.0M | ||
| Q3 25 | $1.0B | $508.0M | ||
| Q2 25 | $1.0B | $696.0M | ||
| Q1 25 | $35.0M | $426.0M | ||
| Q4 24 | $588.0M | $261.0M | ||
| Q3 24 | $882.0M | $593.0M | ||
| Q2 24 | $1.1B | $576.0M |
自由现金流率BDXNXPI
| Q1 26 | — | 22.4% | ||
| Q4 25 | 10.5% | 23.8% | ||
| Q3 25 | 17.0% | 16.0% | ||
| Q2 25 | 19.0% | 23.8% | ||
| Q1 25 | 0.7% | 15.0% | ||
| Q4 24 | 11.4% | 8.4% | ||
| Q3 24 | 16.2% | 18.2% | ||
| Q2 24 | 22.4% | 18.4% |
资本支出强度BDXNXPI
| Q1 26 | — | 2.5% | ||
| Q4 25 | 2.1% | 2.9% | ||
| Q3 25 | 6.0% | 2.4% | ||
| Q2 25 | 3.2% | 2.8% | ||
| Q1 25 | 2.4% | 4.9% | ||
| Q4 24 | 2.0% | 4.2% | ||
| Q3 24 | 5.4% | 5.7% | ||
| Q2 24 | 3.6% | 5.9% |
现金转化率BDXNXPI
| Q1 26 | — | — | ||
| Q4 25 | 1.72× | 1.96× | ||
| Q3 25 | 2.75× | 0.93× | ||
| Q2 25 | 2.12× | 1.75× | ||
| Q1 25 | 0.53× | 1.15× | ||
| Q4 24 | 2.29× | 0.79× | ||
| Q3 24 | 2.94× | 1.08× | ||
| Q2 24 | 2.66× | 1.16× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BDX
| Other | $2.8B | 53% |
| Medication Management Solutions | $678.0M | 13% |
| Urologyand Critical Care | $339.0M | 6% |
| Surgery | $310.0M | 6% |
| Peripheral Intervention | $265.0M | 5% |
| Specimen Management | $245.0M | 5% |
| Advanced Patient Monitoring | $178.0M | 3% |
| Diagnostic Solutions | $176.0M | 3% |
| Bio Pharma Systems | $150.0M | 3% |
| Biosciences | $124.0M | 2% |
NXPI
暂无分部数据
